Further analysis at weeks 2, 4 and 6
hypopigmented lesions, rash
Comparing the percent reduction in the extent of lesions from baseline to weeks 2, 4 and 6 between both groups revealed that NB-UVB achieved significant reduction in the extent of the hypopigmented lesions in weeks 4 and 6 (Biweekly follow-up for percent reduction in the hypopigmented lesions and the rash as a whole in azithromycin and NB-UVB groups